Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown

Aug 17 2017

• By Mandy Jackson

Digital illustration of Cancer cell in colour background

Related Content

Takeda Adds Exelixis Arrow To Oncology Quiver

Jan 31 2017

Value Measures, Side Effects Help Differentiate Drugs In Crowded Kidney Cancer Market

Jun 17 2016

Exelixis Hopes CABOSUN Means New Dawn For Cabometyx In Frontline Kidney Cancer

Oct 10 2016

Kidney Cancer Gets A Double Uplift From Latest CHMP Meeting

Jul 25 2016

Exelixis' Strong Cabometyx Start Signals Changing Of Guard In Kidney Cancer Market

Aug 05 2016

Immuno-Oncology Outlook: Pfizer's Inlyta Fits Well In Combos For Kidney Cancer

Jun 29 2017

Exelixis gains US OK for Cometriq in metastatic medullary thyroid cancer

Nov 30 2012

Liver Cancer: What's Close To The Market

Aug 16 2017

Another Opdivo Disappointment For BMS, This Time In Kidney Cancer

Aug 16 2017

Exelixis’ Cabozantinib Cleared For Kidney Cancer, With Competitive Labeling

Apr 26 2016

Related Companies

Exelixis, Inc.

Bristol Myers Squibb Company

Pfizer Inc.

Merck & Co., Inc.

Roche Holding AG

Merck KGaA

Ipsen SA

Takeda Pharmaceutical Co. Ltd.

Additional Topics

Business Strategies Regulation Commercial Cancer Renal BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window